Parasitology Research

, Volume 110, Issue 2, pp 515–520 | Cite as

Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters

  • Zubeyde Akın Polat
  • Andreas Obwaller
  • Ayse Vural
  • Julia Walochnik
Original Paper

Abstract

Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available. The aim of the study therefore was to assess the therapeutic potential of miltefosine on Acanthamoeba keratitis-infected hamster eyes. The cornea of hamsters were infected with Acanthamoeba hatchetti, a human corneal isolate. On the fifth day, all the cornea were microscopically examined in order to determine the degree of infections (G, from 0 to 3). Four groups were then prepared: miltefosine (160 μM); 0.1% propamidine isetionate plus 0.02% polyhexnide; infected control (0.05% ethanol in PBS) and a non-infected control (0.05% ethanol in PBS) groups. The treatment was continued for 28 days. After the treatment, the cornea were excised and used for Acanthamoeba culture to investigate the presence of Acanthamoeba growth. Miltefosine treatment yielded much higher cure scores than propamidine isetionate plus polyhexanide. On the last day of treatment, 85% of the miltefosine-treated eyes were graded as G0; no changes were observed in the uninfected control group eyes; G3 eyes showed only a partial improvement. Furthermore, no Acanthamoeba cells could be recovered from the miltefosine-treated eye samples. Miltefosine appeared to hold necessary therapeutic properties for the treatment of Acanthamoeba keratitis.

Notes

Acknowledgements

This work was supported by Orphanidis Pharma Research GmbH, Wilhelminenstr. 91/IIf, 1160 Vienna, Austria. The authors also thank Prof. Ali Fazil Yenidünya for his invaluable contribution in the preparation of the manuscript.

References

  1. Aichelburg AC, Walochnik J, Assadian O, Prosch H, Steuer A, Perneczky G, Visvesvara GS, Aspöck H, Vetter N (2008) Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 14:1743–1746PubMedCrossRefGoogle Scholar
  2. Blaha C, Duchêne M, Aspöck H, Walochnik J (2006) In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother 57:273–278PubMedCrossRefGoogle Scholar
  3. Chong EM, Dana MR (2007) Acanthamoeba keratitis. Int Ophthalmol Clin 47:33–46PubMedCrossRefGoogle Scholar
  4. Claerhout I, Goegebuer A, Van Den Broecke C, Kestelyn P (2004) Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol 242:648–653PubMedCrossRefGoogle Scholar
  5. Eibl H, Unger C (1990) Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 17:233–242PubMedCrossRefGoogle Scholar
  6. Elder MJ, Kilvington S, Dart JKG (1994) A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. Invest Ophthalmol Vis Sci 35:1059–1064PubMedGoogle Scholar
  7. Ficker L, Hunter P, Seal D, Wright P (1989) Acanthamoeba keratitis occurring with disposable contact lens wear. Am J Ophthalmol 108:453PubMedGoogle Scholar
  8. Ficker L, Seal D, Warhurst D, Wright P (1990) Acanthamoeba keratitis—resistance to medical therapy. Eye 4:835–838PubMedCrossRefGoogle Scholar
  9. Khandpur S, Chaturvedi P, Kumar U, Khaitan BK, Samantaray JC, Sharma VK (2010) Oral miltefosine in post-kala-azar dermal leishmaniasis—experience in three cases. Int J Dermatol 49:565–569PubMedCrossRefGoogle Scholar
  10. Kumar R, Lloyd D (2002) Recent advances in the treatment of Acanthamoeba keratitis. Clin Infect Dis 35:434–441PubMedCrossRefGoogle Scholar
  11. Lee JE, Oum BS, Choi HY, Yu HS, Lee JS (2007) Cysticidal effect on Acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine. Cornea 26:736–741PubMedCrossRefGoogle Scholar
  12. Lorenzo-Morales J, Martínez-Carretero E, Batista N, Alvarez-Marín J, Bahaya Y, Walochnik J, Valladares B (2007) Early diagnosis of amoebic keratitis due to a mixed infection with Acanthamoeba and Hartmannella. Parasitol Res 102:167–169PubMedCrossRefGoogle Scholar
  13. Marciano-Cabral F, Cabral G (2003) Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 16:273–307PubMedCrossRefGoogle Scholar
  14. McBride J, Ingram PR, Henriquez FL, Roberts CW (2005) Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol 43:629–634PubMedCrossRefGoogle Scholar
  15. Pens CJ, Costa M, Fadanelli C, Caumo K, Rott M (2008) Acanthamoeba spp. and bacterial contamination in contact lens storage cases and the relationship to user profiles. Parasitol Res 103:1241–1245PubMedCrossRefGoogle Scholar
  16. Polat ZA, Ozcelik S, Vural A, Cetin A (2007) Clinical and histologic evaluations of experimental Acanthamoeba keratitis. Parasitol Res 101:1621–1625PubMedCrossRefGoogle Scholar
  17. Reinhard T, Sundmacher R (2000) Clinical aspects and therapy of Acanthamoeba keratitis. Ophthalmologe 97:446–459PubMedCrossRefGoogle Scholar
  18. Santa-Rita RM, Santos Barbosa H, Meirelles MN, de Castro SL (2000) Effect of the alkyllysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 75:219–228PubMedCrossRefGoogle Scholar
  19. Scheid P, Zöller L, Pressmar S, Richard G, Michel R (2008) An extraordinary endocytobiont in Acanthamoeba sp. isolated from a patient with keratitis. Parasitol Res 102:945–950PubMedCrossRefGoogle Scholar
  20. Schuster FL (2002) Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev 15:342–354PubMedCrossRefGoogle Scholar
  21. Seal D (2003) Treatment of Acanthamoeba keratitis. Expert Rev Anti Infect Ther 1:205–208PubMedCrossRefGoogle Scholar
  22. Seifert K, Duchêne M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, Hottkowitz T, Eibl H (2001) Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 45:1505–1510PubMedCrossRefGoogle Scholar
  23. Singhal T, Bajpai A, Kalra V, Kabra SK, Samantaray JC, Satpathy G, Gupta AK (2001) Successful treatment of disseminated Acanthamoeba infection in an immunocompromised patient. Pediatr Infect Dis J 20:623–627PubMedCrossRefGoogle Scholar
  24. Tseng SH, Lin SC, Chen FK (1998) Is polyhexamethylene biguanide alone effective for Acanthamoeba keratitis? Cornea 7:345–347Google Scholar
  25. Varga JH, Wolf TC, Jensen HG, Parmley VC, Rowsey JJ (1993) Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide. Am J Ophthalmol 115:466–470PubMedGoogle Scholar
  26. Verma NK, Dey CS (2004) Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 48:3010–3015PubMedCrossRefGoogle Scholar
  27. Visvesvara GS, Moura H, Schuster FL (2007) Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50:1–26PubMedCrossRefGoogle Scholar
  28. Walochnik J, Duchêne M, Seifert K, Obwaller A, Hottkowitz T, Wiedermann G, Eibl H, Aspöck H (2002) Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother 46:695–701PubMedCrossRefGoogle Scholar
  29. Walochnik J, Obwaller A, Aspock H (2000) Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. Appl Environ Microbiol 66:4408–4413PubMedCrossRefGoogle Scholar
  30. Walochnik J, Obwaller A, Gruber F, Mildner M, Tschachler E, Suchomel M, Duchêne M, Auer H (2009) Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J Antimicrob Chemother 64:539–545PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Zubeyde Akın Polat
    • 1
  • Andreas Obwaller
    • 2
  • Ayse Vural
    • 3
  • Julia Walochnik
    • 4
  1. 1.Department of Medical ParasitologyCumhuriyet University School of MedicineSivasTurkey
  2. 2.Orphanidis Pharma Research GmbHViennaAustria
  3. 3.Department of OphthalmologyCumhuriyet University School of MedicineSivasTurkey
  4. 4.Department of Medical ParasitologyMedical University of ViennaViennaAustria

Personalised recommendations